ERBB2 and breast carcinoma: Around 40% of patients achieve pCR in both the breast and axilla, predominantly in certain biologically aggressive early-stage breast cancers, including triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancers [16].